Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2018-01-16 Major Shareholding Noti…
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
CRISPR AMENDMENT NO. 2
Major Shareholding Notification
2018-01-16 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-01-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-01-09 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a public offering of common shares, including underwriting details, pricing, and legal opinions. It also references press releases about the offering. There are no financial statements or detailed financial performance data included, and the document is focused on the announcement of a financing event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories. The document length is over 6,000 characters, indicating it is not a brief announcement but a substantive filing about financing activity.
2018-01-05 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to a public offering of 5,000,000 common shares by CRISPR Therapeutics AG. It includes detailed offering terms, underwriting information, risk factors, use of proceeds, and legal matters. The document references SEC registration numbers and includes incorporation by reference of prior SEC filings such as annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K). The document is a registration statement prospectus supplement, which is a type of capital raising disclosure document. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an annual report, earnings release, or other report type, but specifically a prospectus supplement for a share offering.
2018-01-05 English
FORM 4 SUBMISSION
Director's Dealing
2018-01-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.